Stage 3 Cervical Cancer Treatment in Ahmedabad — Dr. Nishtha Tripathi Patel is an ESGO-certified gynaecological oncosurgeon offering specialist treatment for stage 3 cervical cancer treatment at Sterling Hospitals, KD Hospital and Welcare Speciality Hospital in Ahmedabad.
On this page
- What this stage means
- Recommended treatment pathway
- Adjuvant therapy
- Outlook and survival data
- Booking
- FAQs
Stage 3 cervical cancer treatment — What does this stage mean?
Stage 3 cervical cancer involves the pelvic side wall, lower third of the vagina, or causes hydronephrosis. Surgery is no longer first-line. Treatment is concurrent chemoradiation: external beam radiation (typically 45-50 Gy) combined with weekly cisplatin, followed by image-guided brachytherapy boost.
For broader information see our cancer overview and treatment page.
Recommended treatment pathway
Stage 3 cervical cancer involves the pelvic side wall, lower third of the vagina, or causes hydronephrosis. Surgery is no longer first-line. Treatment is concurrent chemoradiation: external beam radiation (typically 45-50 Gy) combined with weekly cisplatin, followed by image-guided brachytherapy boost.
Adjuvant therapy
Maintenance immunotherapy with pembrolizumab is being studied. Adequate brachytherapy dose escalation is critical for local control.
Outlook
5-year survival 35-50% depending on bulk of disease and quality of brachytherapy delivery.
External authoritative reference: NCCN Guidelines and ESGO Recommendations.
Booking
For an individualised treatment plan, share your reports on WhatsApp (+91 76988 00333) or book an appointment. Second opinions are available for patients already under care elsewhere.
FAQs
Where is stage 3 cervical cancer treatment performed in Ahmedabad?
Dr. Nishtha Tripathi Patel treats this disease stage at Sterling Hospitals (Sindhubhavan), KD Hospital, and Welcare Speciality Hospital in Ahmedabad. The hospital is chosen based on the specific procedure needed and patient preference.
What is the typical hospital stay?
For minimally invasive surgery (robotic or laparoscopic), hospital stay is typically 3-4 days. For cytoreductive surgery or HIPEC, stay extends to 7-10 days. Chemoradiation is outpatient over 5-7 weeks.
What is the likely outcome?
5-year survival 35-50% depending on bulk of disease and quality of brachytherapy delivery. Outcomes are stage-dependent and individual; the figures above are averages from published series.
Is fertility preservation possible?
Fertility preservation is not standard for this stage. Egg or embryo cryopreservation may be considered before chemotherapy if applicable.
Can I get a second opinion before deciding?
Yes. Share your reports on WhatsApp (+91 76988 00333). Dr. Nishtha provides independent review of stage, pathology, imaging and proposed treatment within 24-48 hours.
Reviewed by Dr. Nishtha Tripathi Patel, MBBS, DGO, DNB, Fellowship Gynaecological Oncology, ESGO-certified.